Institution
Maastricht University
Education•Maastricht, Limburg, Netherlands•
About: Maastricht University is a education organization based out in Maastricht, Limburg, Netherlands. It is known for research contribution in the topics: Population & Health care. The organization has 19263 authors who have published 53291 publications receiving 2266866 citations. The organization is also known as: Universiteit Maastricht & UM.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In key subgroups, including fragile patients, cancer patients, patients presenting with large clots, and those with a history of recurrent VTE, the efficacy and safety of rivaroxaban were similar compared with standard-therapy and was associated with a significantly lower rate of major bleeding.
Abstract: Background
Standard treatment for venous thromboembolism (VTE) consists of a heparin combined with vitamin K antagonists. Direct oral anticoagulants have been investigated for acute and extended treatment of symptomatic VTE; their use could avoid parenteral treatment and/or laboratory monitoring of anticoagulant effects.
502 citations
••
Charité1, United States Department of Veterans Affairs2, Baylor College of Medicine3, University of Padua4, Mayo Clinic5, University of Greifswald6, University of Miami7, Katholieke Universiteit Leuven8, Maastricht University9, Max Delbrück Center for Molecular Medicine10, University of Tübingen11, Cleveland Clinic12, Kyushu University13, University of Belgrade14
TL;DR: Improved standardization of available invasive and noninvasive diagnostic tools and a consensus on their specific use are needed to allow specific diagnosis and stratification of patient cohorts for the implementation of aetiology-based therapies.
Abstract: Inflammatory cardiomyopathy, characterized by inflammatory cell infiltration into the myocardium and a high risk of deteriorating cardiac function, has a heterogeneous aetiology. Inflammatory cardiomyopathy is predominantly mediated by viral infection, but can also be induced by bacterial, protozoal or fungal infections as well as a wide variety of toxic substances and drugs and systemic immune-mediated diseases. Despite extensive research, inflammatory cardiomyopathy complicated by left ventricular dysfunction, heart failure or arrhythmia is associated with a poor prognosis. At present, the reason why some patients recover without residual myocardial injury whereas others develop dilated cardiomyopathy is unclear. The relative roles of the pathogen, host genomics and environmental factors in disease progression and healing are still under discussion, including which viruses are active inducers and which are only bystanders. As a consequence, treatment strategies are not well established. In this Review, we summarize and evaluate the available evidence on the pathogenesis, diagnosis and treatment of myocarditis and inflammatory cardiomyopathy, with a special focus on virus-induced and virus-associated myocarditis. Furthermore, we identify knowledge gaps, appraise the available experimental models and propose future directions for the field. The current knowledge and open questions regarding the cardiovascular effects associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are also discussed. This Review is the result of scientific cooperation of members of the Heart Failure Association of the ESC, the Heart Failure Society of America and the Japanese Heart Failure Society.
502 citations
••
University of Hasselt1, University Medical Center Groningen2, University of Helsinki3, University of Paris4, Maastricht University5, Yale University6, Cleveland Clinic7, University of Florence8, University of Lorraine9, University of Brescia10, National and Kapodistrian University of Athens11, University of Cyprus12, University of Belgrade13, University of Zurich14
TL;DR: The manuscript addresses frequently encountered challenges, such as evaluation of congestion and clinical euvolaemia, assessment of diuretic response/resistance in the treatment of acute heart failure, and an approach towards stepped pharmacologic diUREtic strategies, based upon diuretics response.
Abstract: The vast majority of acute heart failure episodes are characterized by increasing symptoms and signs of congestion with volume overload. The goal of therapy in those patients is the relief of congestion through achieving a state of euvolaemia, mainly through the use of diuretic therapy. The appropriate use of diuretics however remains challenging, especially when worsening renal function, diuretic resistance and electrolyte disturbances occur. This position paper focuses on the use of diuretics in heart failure with congestion. The manuscript addresses frequently encountered challenges, such as (i) evaluation of congestion and clinical euvolaemia, (ii) assessment of diuretic response/resistance in the treatment of acute heart failure, (iii) an approach towards stepped pharmacologic diuretic strategies, based upon diuretic response, and (iv) management of common electrolyte disturbances. Recommendations are made in line with available guidelines, evidence and expert opinion.
498 citations
••
TL;DR: Any potential benefits associated with a moderately elevated protein intake must be evaluated in the light of customary dietary practices and individual variability.
497 citations
••
TL;DR: It is concluded that future anti-vascular therapies might be most beneficial when based on multimodal anti-angiogenic, anti-vasculogenic mimicry and anti-lymphangiogenesis strategies.
Abstract: Tumour angiogenesis is a fast growing domain in tumour biology. Many growth factors and mechanisms have been unravelled. For almost 30 years, the sprouting of new vessels out of existing ones was considered as an exclusive way of tumour vascularisation. However, over the last years several additional mechanisms have been identified. With the discovery of the contribution of intussusceptive angiogenesis, recruitment of endothelial progenitor cells, vessel co-option, vasculogenic mimicry and lymphangiogenesis to tumour growth, anti-tumour targeting strategies will be more complex than initially thought. This review highlights these processes and intervention as a potential application in cancer therapy. It is concluded that future anti-vascular therapies might be most beneficial when based on multimodal anti-angiogenic, anti-vasculogenic mimicry and anti-lymphangiogenic strategies.
497 citations
Authors
Showing all 19492 results
Name | H-index | Papers | Citations |
---|---|---|---|
Edward Giovannucci | 206 | 1671 | 179875 |
Julie E. Buring | 186 | 950 | 132967 |
Aaron R. Folsom | 181 | 1118 | 134044 |
John J.V. McMurray | 178 | 1389 | 184502 |
Alvaro Pascual-Leone | 165 | 969 | 98251 |
Lex M. Bouter | 158 | 767 | 103034 |
David T. Felson | 153 | 861 | 133514 |
Walter Paulus | 149 | 809 | 86252 |
Michael Conlon O'Donovan | 142 | 736 | 118857 |
Randy L. Buckner | 141 | 346 | 110354 |
Philip Scheltens | 140 | 1175 | 107312 |
Anne Tjønneland | 139 | 1345 | 91556 |
Ewout W. Steyerberg | 139 | 1226 | 84896 |
James G. Herman | 138 | 410 | 120628 |
Andrew Steptoe | 137 | 1003 | 73431 |